Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double‐blind, clinical trial

格列美脲 罗格列酮 二甲双胍 医学 内科学 内分泌学 2型糖尿病 代谢综合征 载脂蛋白B 血脂谱 体质指数 糖尿病 胆固醇 胃肠病学
作者
Giuseppe Derosa,A. Gaddi,Mario N. Piccinni,Sibilla Salvadeo,Leonardina Ciccarelli,Elena Fogari,M. Ghelfi,Ilaria Ferrari,Arrigo F.G. Cicero
出处
期刊:Diabetes, Obesity and Metabolism [Wiley]
卷期号:8 (2): 197-205 被引量:43
标识
DOI:10.1111/j.1463-1326.2005.00480.x
摘要

Aim: Accumulating evidence suggests that combination therapy using oral antidiabetic agents with different mechanisms of action may be highly effective in achieving and maintaining target blood glucose levels. The aim of our study is to evaluate the differential effect on glucose and lipid parameters of the association between glimepiride plus metformin and rosiglitazone plus metformin in patients affected by type 2 diabetes and metabolic syndrome. Methods: Patients were enroled, evaluated and followed at two Italian centres. We evaluated 99 type 2 diabetic patients with metabolic syndrome (48 males and 47 females; 23 males and 24 females, aged 52 ± 5 with glimepiride; 25 males and 23 females, aged 54 ± 4 with cglitazone). All were required to have been diagnosed as being diabetic for at least 6 months and did not have glycaemic control with diet and oral hypoglycaemic agents such as sulphonylureas or metformin, both to the maximum tolerated dose. All patients took a fixed dose of metformin, 1500 mg/day. We administered glimepiride (2 mg/day) or rosiglitazone (4 mg/day) in a randomized, controlled, double‐blind clinical study. We evaluated body mass index (BMI), glycaemic control, lipid profile [total cholesterol (TC), low‐density lipoprotein‐cholesterol (LDL‐C), high‐density lipoprotein‐cholesterol and triglycerides] and lipoprotein parameters [apolipoprotein A‐I and apolipoprotein B (Apo B)] during 12 months of this treatment. Results: A total of 95 patients completed the study. Significant BMI decrease was observed at 12 months in glimepiride and rosiglitazone group (p < 0.05 and p < 0.01 respectively) as well as of glycated haemoglobin decrease (p < 0.05 and p < 0.01 respectively), mean fasting plasma glucose and postprandial plasma glucose levels (p < 0.05 and p < 0.01 respectively). A decrease in fasting plasma insulin and postprandial plasma insulin at 12 months (p < 0.05 and p < 0.01 respectively) compared with the baseline value in rosiglitazone group was observed. Furthermore, homeostasis model assessment index improvement was obtained only at 9 and 12 months (p < 0.05 and p < 0.01 respectively) compared with the baseline value in rosiglitazone group. Significant TC, LDL‐C and Apo B improvement (p < 0.05 respectively) was present in glimepiride group after 12 months compared with the baseline values, and these variations were significant (p < 0.05) between groups. Of the 95 patients who completed the study, 8.5% of patients in glimepiride group and 12.5% of patients in rosiglitazone group had side‐effects (p = not significant). Four patients had transient side‐effects in glimepiride group and six patients in rosiglitazone group. Altogether, we did not have statistically significant changes in transaminases. Conclusions: The rosiglitazone–metformin association significantly improve the long‐term control of all insulin‐resistance‐related parameters in comparison with the glimepiride–metformin‐treated group. On the other side, glimepiride treatment is associated to a slight improvement in cholesterolaemia, not observed in the rosiglitazone‐treated patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
法国v刚刚发布了新的文献求助10
刚刚
郑思怀完成签到,获得积分10
2秒前
刘刘发布了新的文献求助10
3秒前
3秒前
SpaceThing完成签到,获得积分10
5秒前
5秒前
酱油完成签到,获得积分10
5秒前
6秒前
CAOHOU的应助被初景采纳,获得10
6秒前
canon发布了新的文献求助50
6秒前
6秒前
田様的应助被聪明延恶采纳,获得10
7秒前
Wynne完成签到,获得积分10
8秒前
8秒前
暮飘飘发布了新的文献求助10
9秒前
9秒前
dato12423完成签到,获得积分10
10秒前
kelly1122发布了新的文献求助10
10秒前
壮观的夏云完成签到,获得积分10
10秒前
11秒前
海盗船长发布了新的文献求助10
11秒前
悦耳半梦发布了新的文献求助10
11秒前
may发布了新的文献求助10
11秒前
小酒窝完成签到,获得积分10
12秒前
13秒前
13秒前
13秒前
田様的应助被Jonathan采纳,获得10
14秒前
酱酱酱紫完成签到,获得积分10
14秒前
道友等等我完成签到,获得积分0
15秒前
16秒前
透视眼完成签到,获得积分10
16秒前
Jacky发布了新的文献求助10
18秒前
kelly1122完成签到,获得积分20
20秒前
玩命的语薇完成签到,获得积分10
20秒前
cc发布了新的文献求助10
21秒前
21秒前
CipherSage的应助被Jeremy采纳,获得10
22秒前
22秒前
小壶椰椰发布了新的文献求助10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8191370
求助须知:如何正确求助?哪些是违规求助? 9578255
关于积分的说明 21857784
捐赠科研通 7790730
什么是DOI,文献DOI怎么找? 3436626
关于科研通互助平台的介绍 2560360
邀请新用户注册赠送积分活动 2483366